查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
到 2030 年胃食道逆流症市场预测：按产品、药物类型、诊断、给药途径、配销通路、最终用户和地区进行的全球分析
市场调查报告书
商品编码
1383353

到 2030 年胃食道逆流症市场预测：按产品、药物类型、诊断、给药途径、配销通路、最终用户和地区进行的全球分析

Gastroesophageal Reflux Disease Market Forecasts to 2030 - Global Analysis By Product, Drug Type, Diagnosis, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球胃食道逆流症市场规模为 53.7 亿美元，预计到 2030 年将达到 69.3 亿美元，预测期内年复合成长率为 3.7%。

胃灼热是一种由胃食道逆流症 (GERD) 引起的灼热感。此外，逆流是一种向后运动，当胃内容物（包括盐酸）再次向上移动时，会导致食道下部有灼热感。

根据美国国家生物技术资讯中心 (NCBI) 2022 年 5 月更新的一篇论文，吸烟被认为是胃酸倒流或酸逆流的病因因素，并且是 50 岁以上人群胃酸倒流的主要危险因素。已经被考虑了。

药物开发的新方法

製药业专注于 GERD 的研究和开发，从而开发出安全有效的治疗方法。除了开发新配方外，创新还包括个人化医疗策略，根据生活方式和遗传因素为特定患者量身定制治疗方法。透过解决巴雷特食道、食道癌和呼吸系统疾病等 GERD 相关併发症，这些创新提供了更全面的治疗和预防方法。

药物滥用和副作用

质子帮浦抑制剂（PPI）是一种用于治疗胃食道逆流的药物，但由于副作用风险，不宜长期使用。儘管 PPI 很有用，但它们会导致肾功能、骨骼健康和营养吸收不良等问题。此外，患者和医疗保健专业人员很难控制这些副作用并平衡短期症状缓解与长期健康。

诊断设备技术

早期准确诊断 GERD 的一个关键机会是诊断设备的持续改进所带来的，例如高解析度食道检测、动态 pH 监测以及共焦雷射内视镜等先进内视镜方法。这些设备可以更轻鬆地评估食道损伤的程度，检测巴雷特食道等併发症，并为选定的患者选择最佳治疗方法。此外，透过获得更快、更准确的诊断，您可以获得更有效和个体化的治疗，以缓解症状并预防长期问题。

对药物治疗的耐受性和抗药性

特别是质子帮浦抑制剂（PPI）不宜长期使用，因为有些患者可能会产生抗药性或耐受性。随着时间的推移，这些药物可能会变得不太有效，需要更高的给药或其他药物。此外，寻求更强效药物或更多治疗方法来控制症状的患者可能会对处方药物产生抗药性，使治疗决策更加困难并增加医疗费用。

COVID-19 的影响：

胃食道逆流症 (GERD) 和全球医疗保健市场都受到了 COVID-19大流行的严重影响。虽然疫情最初对医疗保健服务和供应链造成了干扰，包括胃食道逆流药物和医疗设备的製造和分销，但也为病患行为和医疗保健服务带来了重大变化。此外，关门和其他社交疏远措施导致胃食道逆流症患者远端医疗和远端监控的使用激增，使他们能够继续接受治疗，同时降低感染病毒的风险。

胶囊细分市场预计将在预测期内成为最大的细分市场

胶囊预计将在胃食道逆流症领域占据最大的市场占有率。胶囊因其适应性强、易于製造和对患者友好的特性而被广泛使用。胶囊提供了一种实用且有效的方式来递送各种药物製剂，例如液体、半固体和固体物质。胶囊受到所有年龄层患者的青睐，因为它们剂量精确且易于吞嚥，使其成为处方药和成药的热门选择。此外，胶囊还可用于广泛的治疗应用，包括特殊药物、维生素、草药补充剂和抗生素的配製。

家庭护理产业预计在预测期内年复合成长率最高

在预测期内，年复合成长率最高的将是家庭护理领域。由于高龄化、对舒适环境中个人化照护的渴望以及远端医疗和医疗技术的进步等多种因素，对家庭护理服务的需求正在显着增加。此外，居家照护服务涵盖广泛的医疗和非医疗支持，这对需要在舒适的家中持续照护、监测和復原的患者俱有吸引力。根据患者的需求，这可能包括物理治疗、药物管理、护理，甚至复杂的医疗程序。

占比最大的地区：

预计北美地区将占据最大的市场占有率。该地区因多种原因而闻名，包括强大的製药和医疗设备产业、广泛的医疗基础设施以及高昂的医疗支出。美国製药业实力雄厚，尤其是在药物研发和技术创新方面。北美优势的另一个因素是其拥有丰富的国际认可的研究中心和医疗设施。此外，北美医疗保健市场不断变化，越来越重视基于价值的护理、创新治疗方法和医疗技术。

复合年复合成长率最高的地区：

市场年复合成长率最高的是亚太地区。多种因素促成了这一强劲增长，包括人口快速增长、都市化加快、医疗保健意识增强以及中国和印度等国家经济的显着发展。这些国家正在药品、医疗技术和医疗保健基础设施方面进行大量投资。此外，亚太地区已成为着名的临床试验和研究中心，吸引了来自世界各地的製药和医疗设备製造商。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球胃食道逆流症市场：副产品

  • 锭剂
  • 胶囊
  • 暂停
  • 解决方案
  • 其他产品

第6章全球胃食道逆流症市场：依药物类型

  • 抗酸剂
  • 质子帮浦抑制剂
  • H2受体阻断剂
  • 促动力剂
  • 多巴胺受体拮抗
  • 末端係紧
  • 史特雷塔
  • 食道
  • 无经口切口
  • 胃底折迭术
  • 其他类型的药物

第7章全球胃食道逆流症市场：依诊断

  • 上内视镜
  • 国外酸（pH）探针测试
  • 食道压力检测
  • 其他诊断

第8章全球胃食道逆流症市场：依给药途径

  • 口服
  • 静脉

第9章全球胃食道逆流症市场：按配销通路

  • 医院药房
  • 网路药房
  • 零售药房

第10章全球胃食道逆流症市场：依最终用户分类

  • 医院
  • 居家护理
  • 专科诊所
  • 其他最终用户

第11章全球胃食道逆流症市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第12章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第13章公司简介

  • Medtronic Plc
  • Takeda Pharmaceutical Company Limited.
  • Johnson & Johnson Services Inc.
  • GlaxoSmithKline PLC
  • Olympus Corporation
  • TWi Pharmaceuticals, Inc.
  • Ironwood Pharmaceuticals, Inc.
  • SRS Life Sciences
  • Reckitt Benckiser Group PLC
  • Zydus Group
  • AstraZeneca PLC
  • Camber Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Teva Pharmaceuticals Industries Limited.
  • Aurobindo Pharma
  • Sebela Pharmaceuticals
  • Phathom Pharmaceuticals, Inc.
  • SFJ Pharmaceuticals
Product Code: SMRC24203

According to Stratistics MRC, the Global Gastroesophageal Reflux Disease Market is accounted for $5.37 billion in 2023 and is expected to reach $6.93 billion by 2030 growing at a CAGR of 3.7% during the forecast period. Heartburn is a burning sensation that is brought on by a condition called gastroesophageal reflux disease (GERD). Moreover, reflux, a backward movement that produces a burning sensation in the lower part of the esophagus, is what happens when the stomach's hydrochloric acid-containing contents travel upward again.

According to an article updated by the National Center for Biotechnology Information (NCBI) in May 2022, tobacco smoking is considered an etiological factor of reflux esophagitis or acid reflux and it is considered a major risk factor for acid reflux over the age of 50.

Market Dynamics:

Driver:

New approaches to drug development

The pharmaceutical industry's dedication to GERD research and development has resulted in the development of increasingly safe and effective drugs for the condition's management. Additionally, innovations include not only the creation of new drug formulations but also personalized medicine strategies that customize treatments for specific patients based on lifestyle and genetic factors. By addressing GERD-related complications like Barrett's esophagus, esophageal cancer, and respiratory disorders, these innovations offer a more all-encompassing approach to treatment and prevention.

Restraint:

Overuse and adverse reactions to medication

Proton pump inhibitors (PPIs), one type of medication used to treat GERD should not be used for an extended period of time due to the risk of side effects. PPIs are useful, but they raise questions about kidney function, bone health, and nutrient malabsorption. Furthermore, it can be difficult for patients and healthcare professionals to manage these side effects and strike a balance between short-term symptom relief and long-term health.

Opportunity:

Technologies for diagnostic instruments

An important opportunity for the early and precise diagnosis of GERD is provided by continuous improvements in diagnostic tools, such as high-resolution esophageal manometry, ambulatory pH monitoring, and sophisticated endoscopy methods like confocal laser endomicroscopy. These instruments facilitate the evaluation of the degree of esophageal injury, the detection of complications such as Barrett's esophagus, and the choice of the best course of action for selected patients. Moreover, patients can receive more effective and individualized treatments aimed at symptom relief and long-term problem prevention with an earlier and more accurate diagnosis.

Threat:

Tolerance and resistance to medication

Proton pump inhibitors (PPIs) in particular should not be used for extended periods of time, as some patients may develop drug resistance and tolerance. It is possible that these drugs will lose their effectiveness with time and that higher doses or other medications will be necessary. Additionally, patients who seek stronger medications or more therapies to manage their symptoms may become resistant to their prescribed medications, which can make treatment decisions more difficult and raise medical expenses.

COVID-19 Impact:

Gastroesophageal reflux disease (GERD) and the global healthcare market have both been significantly impacted by the COVID-19 pandemic. Significant changes in patient behavior and healthcare delivery were also brought about by the pandemic, even though it first caused disruptions to healthcare services and supply chains, including the manufacture and distribution of GERD medications and medical devices. Furthermore, lockdowns and other social distancing measures led to a spike in the use of telemedicine and remote monitoring for GERD patients, which allowed for continued care while lowering the risk of contracting the virus.

The Capsule segment is expected to be the largest during the forecast period

It is projected that the capsule segment will command the largest market share for gastroesophageal reflux disease. Because of their adaptability, simplicity in production, and patient-friendly qualities, capsules are widely used. They offer a practical and efficient means of delivering a variety of pharmaceutical formulations, such as liquid, semi-solid, or solid substances. Patients of all ages prefer capsules because they provide accurate dosing and ease of swallowing, making them a popular choice for both prescription and over-the-counter medications. Furthermore, capsules can be used for a wide range of therapeutic applications, including the formulation of specialty drugs, vitamins, herbal supplements, and antibiotics.

The Homecare segment is expected to have the highest CAGR during the forecast period

Over the course of the projection period, the homecare segment has shown the highest CAGR. The need for homecare services has increased significantly as a result of a number of factors, such as the aging population, the desire for individualized care in comfortable settings, and developments in telehealth and medical technology. Moreover, homecare services are appealing for patients who need ongoing care, monitoring, or rehabilitation while remaining in their own homes because they cover a wide range of medical and non-medical assistance. Depending on the patient's needs, these services can include physical therapy, medication management, nursing care, and even complex medical procedures.

Region with largest share:

The region of North America is projected to possess the largest market share. The region is well-known for a number of reasons, including a strong pharmaceutical and medical device industry, a large healthcare infrastructure, and high healthcare spending. Particularly in terms of drug development and innovation, the pharmaceutical industry in the United States is substantial. Another factor in North America's dominance is the abundance of internationally recognized research centers and healthcare facilities. Additionally, the North American healthcare market is still changing, with an increasing emphasis on value-based care, innovative therapies, and medical technology.

Region with highest CAGR:

The market's highest CAGR is being experienced by the Asia-Pacific region. Numerous factors, such as the fast-growing population, growing urbanization, increased awareness of healthcare, and significant economic development in nations like China and India, can be credited for this robust growth. These countries are seeing large investments in pharmaceuticals, medical technology, and healthcare infrastructure. Furthermore, the Asia-Pacific area is becoming known as a center for clinical trials and research, drawing pharmaceutical and medical device manufacturers from throughout the world.

Key players in the market

Some of the key players in Gastroesophageal Reflux Disease market include: Medtronic Plc, Takeda Pharmaceutical Company Limited., Johnson & Johnson Services Inc., GlaxoSmithKline PLC, Olympus Corporation, TWi Pharmaceuticals, Inc, Ironwood Pharmaceuticals, Inc., SRS Life Sciences, Reckitt Benckiser Group PLC, Zydus Group, AstraZeneca PLC, Camber Pharmaceuticals, Inc., Pfizer Inc., Teva Pharmaceuticals Industries Limited., Aurobindo Pharma, Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc. and SFJ Pharmaceuticals.

Key Developments:

In May 2023, Medtronic plc, a global leader in healthcare technology, today announced it has entered into a set of definitive agreements to acquire EOFlow Co. Ltd., manufacturer of the EOPatch® device a tubeless, wearable and fully disposable insulin delivery device. The addition of EOFlow, together with Medtronic's Meal Detection Technology™ algorithm and next-generation continuous glucose monitor, is expected to expand the company's ability to address the needs of more individuals with diabetes, no matter where they are in their treatment journey or preference for how they want their insulin delivered.

In May 2023, Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.

In January 2023, Takeda has signed an exclusive licence agreement with HUTCHMED (China) and its subsidiary HUTCHMED to develop and market the latter's fruquintinib. Under the deal terms, the company will have an exclusive global licence for the development and commercialisation of fruquintinib for all indications and territories outside of mainland China, Macau, and Hong Kong.

Products Covered:

  • Tablet
  • Capsule
  • Suspension
  • Solution
  • Other Products

Drug Types Covered:

  • Antacids
  • Proton Pump Inhibitors
  • H2 Receptor Blocker
  • Pro Kinetic Agents
  • Dopamine Receptor Antagonist
  • EndoCinch
  • Stretta
  • EsophyX
  • Transoral Incisionless
  • Fundoplication
  • Other Drug Types

Diagnosis Covered:

  • Upper Endoscopy
  • Ambulatory Acid (pH) Probe Test
  • Esophageal Manometry
  • Other Diagnosis

Route of Administrations Covered:

  • Oral
  • Parental

Distribution Channels Covered:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

End Users Covered:

  • Hospital
  • Homecare
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Gastroesophageal Reflux Disease Market, By Product

  • 5.1 Introduction
  • 5.2 Tablet
  • 5.3 Capsule
  • 5.4 Suspension
  • 5.5 Solution
  • 5.6 Other Products

6 Global Gastroesophageal Reflux Disease Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Antacids
  • 6.3 Proton Pump Inhibitors
  • 6.4 H2 Receptor Blocker
  • 6.5 Pro Kinetic Agents
  • 6.6 Dopamine Receptor Antagonist
  • 6.7 EndoCinch
  • 6.8 Stretta
  • 6.9 EsophyX
  • 6.10 Transoral Incisionless
  • 6.11 Fundoplication
  • 6.12 Other Drug Types

7 Global Gastroesophageal Reflux Disease Market, By Diagnosis

  • 7.1 Introduction
  • 7.2 Upper Endoscopy
  • 7.3 Ambulatory Acid (pH) Probe Test
  • 7.4 Esophageal Manometry
  • 7.5 Other Diagnosis

8 Global Gastroesophageal Reflux Disease Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Oral
  • 8.3 Parental

9 Global Gastroesophageal Reflux Disease Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacy
  • 9.3 Online Pharmacy
  • 9.4 Retail Pharmacy

10 Global Gastroesophageal Reflux Disease Market, By End User

  • 10.1 Introduction
  • 10.2 Hospital
  • 10.3 Homecare
  • 10.4 Specialty Clinics
  • 10.5 Other End Users

11 Global Gastroesophageal Reflux Disease Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Medtronic Plc
  • 13.2 Takeda Pharmaceutical Company Limited.
  • 13.3 Johnson & Johnson Services Inc.
  • 13.4 GlaxoSmithKline PLC
  • 13.5 Olympus Corporation
  • 13.6 TWi Pharmaceuticals, Inc.
  • 13.7 Ironwood Pharmaceuticals, Inc.
  • 13.8 SRS Life Sciences
  • 13.9 Reckitt Benckiser Group PLC
  • 13.10 Zydus Group
  • 13.11 AstraZeneca PLC
  • 13.12 Camber Pharmaceuticals, Inc.
  • 13.13 Pfizer Inc.
  • 13.14 Teva Pharmaceuticals Industries Limited.
  • 13.15 Aurobindo Pharma
  • 13.16 Sebela Pharmaceuticals
  • 13.17 Phathom Pharmaceuticals, Inc.
  • 13.18 SFJ Pharmaceuticals

List of Tables

  • Table 1 Global Gastroesophageal Reflux Disease Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Gastroesophageal Reflux Disease Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Gastroesophageal Reflux Disease Market Outlook, By Tablet (2021-2030) ($MN)
  • Table 4 Global Gastroesophageal Reflux Disease Market Outlook, By Capsule (2021-2030) ($MN)
  • Table 5 Global Gastroesophageal Reflux Disease Market Outlook, By Suspension (2021-2030) ($MN)
  • Table 6 Global Gastroesophageal Reflux Disease Market Outlook, By Solution (2021-2030) ($MN)
  • Table 7 Global Gastroesophageal Reflux Disease Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 8 Global Gastroesophageal Reflux Disease Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 9 Global Gastroesophageal Reflux Disease Market Outlook, By Antacids (2021-2030) ($MN)
  • Table 10 Global Gastroesophageal Reflux Disease Market Outlook, By Proton Pump Inhibitors (2021-2030) ($MN)
  • Table 11 Global Gastroesophageal Reflux Disease Market Outlook, By H2 Receptor Blocker (2021-2030) ($MN)
  • Table 12 Global Gastroesophageal Reflux Disease Market Outlook, By Pro Kinetic Agents (2021-2030) ($MN)
  • Table 13 Global Gastroesophageal Reflux Disease Market Outlook, By Dopamine Receptor Antagonist (2021-2030) ($MN)
  • Table 14 Global Gastroesophageal Reflux Disease Market Outlook, By EndoCinch (2021-2030) ($MN)
  • Table 15 Global Gastroesophageal Reflux Disease Market Outlook, By Stretta (2021-2030) ($MN)
  • Table 16 Global Gastroesophageal Reflux Disease Market Outlook, By EsophyX (2021-2030) ($MN)
  • Table 17 Global Gastroesophageal Reflux Disease Market Outlook, By Transoral Incisionless (2021-2030) ($MN)
  • Table 18 Global Gastroesophageal Reflux Disease Market Outlook, By Fundoplication (2021-2030) ($MN)
  • Table 19 Global Gastroesophageal Reflux Disease Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 20 Global Gastroesophageal Reflux Disease Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 21 Global Gastroesophageal Reflux Disease Market Outlook, By Upper Endoscopy (2021-2030) ($MN)
  • Table 22 Global Gastroesophageal Reflux Disease Market Outlook, By Ambulatory Acid (pH) Probe Test (2021-2030) ($MN)
  • Table 23 Global Gastroesophageal Reflux Disease Market Outlook, By Esophageal Manometry (2021-2030) ($MN)
  • Table 24 Global Gastroesophageal Reflux Disease Market Outlook, By Other Diagnosis (2021-2030) ($MN)
  • Table 25 Global Gastroesophageal Reflux Disease Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 26 Global Gastroesophageal Reflux Disease Market Outlook, By Oral (2021-2030) ($MN)
  • Table 27 Global Gastroesophageal Reflux Disease Market Outlook, By Parental (2021-2030) ($MN)
  • Table 28 Global Gastroesophageal Reflux Disease Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 29 Global Gastroesophageal Reflux Disease Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 30 Global Gastroesophageal Reflux Disease Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 31 Global Gastroesophageal Reflux Disease Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 32 Global Gastroesophageal Reflux Disease Market Outlook, By End User (2021-2030) ($MN)
  • Table 33 Global Gastroesophageal Reflux Disease Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 34 Global Gastroesophageal Reflux Disease Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 35 Global Gastroesophageal Reflux Disease Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 36 Global Gastroesophageal Reflux Disease Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.